Lymphomatoid papulosis: a clinical and histopathologic review and follow-up study of 34 cases in Taiwan

Background: Lymphomatoid papulosis (LyP) is a rare condition within the spectrum of CD30+ cutaneous lymphoproliferative disorders that is not well documented in Taiwan. This study aimed to analyze its clinical manifestations, diagnostic histopathology, clinical course, and treatment response among T...

Full description

Saved in:
Bibliographic Details
Main Authors: Jheng-Wei Lin (Author), Wen-Jin Shiau (Author), Ching-I. Lu (Author), Chang-You Tsai (Author), Wen-Ron Wong (Author), Rosaline Chung-Yee Hui (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2011-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Lymphomatoid papulosis (LyP) is a rare condition within the spectrum of CD30+ cutaneous lymphoproliferative disorders that is not well documented in Taiwan. This study aimed to analyze its clinical manifestations, diagnostic histopathology, clinical course, and treatment response among Taiwanese. Methods: A retrospective chart review was performed on patients diagnosed with LyP at a Taiwanese medical center from 1992 to 2008. Results: There were 34 patients with biopsy-proven LyP. The mean age at diagnosis was 36 years (range: 10-75 years), with male predominance (male:female ratio 3:2). Type-A LyP was identified in 32 patients and Type C in 2 patients. Seven cases showed CD4 predominance and six cases showed CD8 predominance. Of the 34 LyP patients, 2 had coexistent non-Hodgkin's lymphoma, 1 (3%, 1/34) diagnosed before LyP onset and 1 (3%, 1/34) developed lymphoma 3 years after LyP. All of the patients were alive after a mean of 5.2 years (range: 3-12.7 years) of follow-up. Conclusions: Most of our cases are Type A LyP. No clinical features or pathologic features can predict increased risk for developing malignancy. Although only 6% (2/34) of LyP patients were found to have lymphoma in 3-year follow-up, longer follow up is needed. Regardless of treatment modalities, two-thirds of the patients have a recurrent and relapsing course. Observation is a reasonable approach for patients without cosmetic or symptomatic concerns.
Item Description:1027-8117
10.1016/j.dsi.2011.02.001